Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Heart Failure (ULTIMATE-HF)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Udenafil (Primary)
Indications Heart failure
Focus Therapeutic Use
Acronyms ULTIMATE-HF

Most Recent Events

31 Mar 2014 Primary endpoint 'Maximal-oxygen-consumption' has been met according to results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
31 Mar 2014 Results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
11 Apr 2013 Planned End Date changed from 1 Feb 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight